Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
13'-carboxychromanol
- Development stage
- Preclinical
- Lead developer
- DSM Nutritional Products, Inc.
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
13'-carboxychromanol is a research-stage small molecule and an endogenous long-chain metabolite of vitamin E (specifically derived from δ-tocotrienol and α-tocopherol) produced via omega-oxidation. It functions as a potent anti-inflammatory and anti-proliferative agent by inhibiting cyclooxygenases (COX-1 and COX-2) and 5-lipoxygenase (5-LOX). Additionally, it modulates lipid metabolism by inhibiting the SREBP1-SCD1 axis and interrupts de novo sphingolipid synthesis by inhibiting dihydroceramide desaturase (DEGS), leading to the accumulation of dihydroceramides and induction of apoptosis in cancer cells. Preclinical research, supported in part by DSM Nutritional Products, has explored its potential in treating ulcerative colitis, colon cancer, and pancreatic cancer.
- Other names
- 13'-carboxychromanol13'-carboxytocopherol13'-carboxytocotrienol
02
Targets
SREBP-1 / SREBF1 (SREBP-1)SCD1 (Stearoyl-CoA desaturase 1)PGHS-1 (Prostaglandin G/H Synthase 1)PTGES (Microsomal prostaglandin E synthase-1)ALOX5 (Arachidonate 5-lipoxygenase)DEGS1 (Delta(4)-desaturase, sphingolipid 1)
Beyond the preview
Go deeper on 13'-carboxychromanol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 13'-carboxychromanol.